Personally identifiable information (PII) may include your name, birth date, address, phone number, e-mail address or any other information which might reasonably be used to identify you individually. Vyera collects personally identifiable information from web site visitors only when it is voluntarily provided. Vyera will not otherwise collect this information from you on our web site. At those portions of our web site where we provide you with the option to input personally identifiable information, we notify you of the uses we intend to make of that information in any given instance. When Vyera receives PII, we may use it for reasonable business purposes, just as non-Internet businesses do. For example, we may use this information to contact you, via e-mail or regular mail, and to provide you with information we believe may be of interest. It might also be used for compiling data and analyses to understand and serve our customers' needs. Data is also compiled to evaluate the use and utility of the services we provide on-line.
The Vyera web site may also collect information from you that is not personally identifiable. For example, we might track information about the date and time visitors access our site, the type of web browser they used, and the web site from which they connected to our site. Our web sites collect this information by depositing certain bits of information called "cookies" in a visitor's computer. This technology does not collect an individual visitor's personally identifiable information. Rather, this information is collected in an aggregate form. The cookies can tell us how and when pages in a web site were visited and by how many people. This aggregate information will enable us to improve our web sites to serve and inform you better. It also may allow you to shortcut access to points of interest on our web site when you re-enter our system. Attaching this device to your system has no effect on how it performs. If you want to opt-out of this data collection, please click here and follow the instructions, as provided.
As a resource to our visitors, Vyera may provide links to other web sites. We try to carefully choose web sites, which we believe are useful and meet our high standards for the accuracy and utility of information. However, because web site design and content can change so quickly, we cannot guarantee the standards of every web site to which we link. Likewise, we are not responsible for the content of any non-Vyera site. We also cannot guarantee the privacy policies of these other sites and suggest you check the privacy policies of those sites directly.
If you wish to stop receiving any e-mails or other consumer communications from Vyera which may be sent to you in the future based on your request for this information, or if you have submitted personally identifiable information through a Vyera web site and would like to have that information deleted from our records, please notify us regarding your desire to “opt-out” via the the contact information on this site. Your wishes in these matters will be honored. Please note that if you choose to opt-out as described, we will not be able to remove PII about you from the databases of those third parties with which we have already shared your PII as of the date that we implement your opt-out request. If you wish to cease receiving promotional emails from such third parties, please contact them directly or utilize any opt-out mechanism set forth in their respective privacy policies or email communications.
Vyera will make every effort to maintain the accuracy and confidentiality of any personal information you supply to us. If you wish to make additions or other corrections to the information that you have sent in, please transmit it to us via the the contact information on this site.
All information transmitted to this Vyera web site is secure to the extent possible using reasonable organizational, technical and administrative measures and existing technology. Unauthorized third parties should not be able to access information during transmission. We will store the information that you share with us securely and will take appropriate steps to protect it from unauthorized access or disclosure. While no security steps can offer 100 percent protection, we utilize state-of-the-art technology and systems to prevent unauthorized access to the information we hold. We will limit access to this information to those Vyera personnel with a need to know. We educate our staff about their duty to protect your privacy. It is your personal responsibility to secure your own copies of your passwords and related access codes for our online resources.
We and our service providers may use “cookies” on the site. A cookie is a bit of information that a website sends to your web browser that helps the site remember information about you and your preferences. You can set your browser to accept all cookies, to reject all cookies, or to notify you whenever a cookie is offered so that you can decide each time whether to accept it. To learn more about cookies, please visit http://www.allaboutcookies.org/.
Vyera does not intentionally or knowingly collect or retain personally identifiable information about children who are younger than 18 years of age. If your child may have submitted information to us without indicating their actual age, and you would like it removed, please advise us through the the contact information on this site, and we will delete it immediately.
Thank you for visiting the Vyera web site. We value your interest and ideas. If you have any comments or concerns regarding the use of information provided to Vyera via an Internet site, please contact us via the contact information on this site.
VECAMYL (mecamylamine hydrochloride 25 mg tablet) - IMPORTANT SAFETY INFORMATION
VECAMYL should not be used in patients with mild, moderate, labile hypertension and may prove unsuitable in uncooperative patients. It should also not be given to patients with coronary insufficiency or recent myocardial infarction.
VECAMYL is contraindicated for patients with uremia, and should be used with caution in patients with renal insufficiency revealed by elevated BUN.
In general, patients receiving antibiotics and sulfonamides should not be treated with VECAMYL.
VECAMYL is also contraindicated for patients with glaucoma, organic pyloric stenosis, or hypersensitivity to mecamylamine hydrochloride.
Tremor, choreiform movements, mental aberrations, and convulsions may occur rarely due to the ability of mecamylamine to readily penetrate into the brain and consequently cause central nervous system effects. These effects have occurred most often following large doses of VECAMYL, particularly in patients with cerebral or renal insufficiency.
When discontinuing VECAMYL, the drug should be withdrawn gradually and other antihypertensive therapy usually must be substituted. Sudden discontinuation of VECAMYL can cause hypertension to abruptly return, which in certain patients, for example those with malignant hypertension, may cause fatal cerebral events or acute congestive heart failure. The effects of VECAMYL may last for hours to days after stopping therapy.
Prior to prescribing VECAMYL, a patient's condition should be evaluated, particularly with respect to renal and cardiovascular function. Additional impairment resulting from hypotension in patients deficient in renal, cerebral, or coronary blood flow must be avoided. VECAMYL should be used with caution in patients with marked cerebral and coronary arteriosclerosis or who have had a recent cerebral vascular accident.
The action of VECAMYL may be potentiated by excessive heat, fever, infection, hemorrhage, pregnancy, anesthesia, surgery, vigorous exercise, other antihypertensive drugs, alcohol, and salt depletion due to diminished salt intake or increased salt excretion as a result of diarrhea, vomiting, excessive sweating, or diuretics.
Patients with prostatic hypertrophy, bladder neck obstruction, or urethral stricture should be treated with caution since urinary retention may occur with VECAMYL.
VECAMYL should immediately be discontinued and remedial steps taken if a patient has signs of paralytic ileus, such as frequent loose bowel movements with abdominal distention and decreased borborygmi.
Patients receiving antibiotics and sulfonamides generally should not be treated with VECAMYL.
The action of VECAMYL may be potentiated by anesthesia, other antihypertensive drugs, and alcohol.
VECAMYL is a potent, oral antihypertension agent and ganglion blocker.
VECAMYL is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.
You are about to enter a site that is for US healthcare professionals only. By clicking “Confirm” below, you certify that you are a healthcare professional and that you wish to proceed to the Healthcare Professionals Only section of this site. Products or treatments described on this site are available in the US but may not be available in other countries.
I am a licensed healthcare professional and wish to proceed to the Healthcare Professionals section of this site.Confirm